Neutralizing Antibody Sample Testing and Report Harmonization.

Immunogenicity testing and characterization is an important part of understanding the immune response to administration of a protein therapeutic. Neutralizing antibody (NAb) assays are used to characterize a positive anti-drug antibody (ADA) response. Harmonization of reporting of NAb assay performance and results enables efficient communication and expedient review by industry and health authorities. Herein, a cross-industry group of NAb assay experts have harmonized NAb assay reporting recommendations and provided a bioanalytical report (BAR) submission editable template developed to facilitate agency filings. This document addresses key bioanalytical reporting gaps and provides a report structure for documenting clinical NAb assay performance and results. This publication focuses on the content and presentation of the NAb sample analysis report including essential elements such as the method, critical reagents and equipment, data analysis, study samples, and results. The interpretation of immunogenicity data, including the evaluation of the impact of NAb on safety, exposure, and efficacy, is out of scope of this publication.

Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development.

The emerging use of qPCR and dPCR in regulated bioanalysis and absence of regulatory guidance on assay validations for these platforms has resulted in discussions on lack of harmonization on assay design and appropriate acceptance criteria for these assays. Both qPCR and dPCR are extensively used to answer bioanalytical questions for novel modalities such as cell and gene therapies. Following cross-industry conversations on the lack of information and guidelines for these assays, an American Association of Pharmaceutical Scientists working group was formed to address these gaps by bringing together 37 industry experts from 24 organizations to discuss best practices to gain a better understanding in the industry and facilitate filings to health authorities. Herein, this team provides considerations on assay design, development, and validation testing for PCR assays that are used in cell and gene therapies including (1) biodistribution; (2) transgene expression; (3) viral shedding; (4) and persistence or cellular kinetics of cell therapies.

Neutralizing Antibody Validation Testing and Reporting Harmonization.

Evolving immunogenicity assay performance expectations and a lack of harmonized neutralizing antibody validation testing and reporting tools have resulted in significant time spent by health authorities and sponsors on resolving filing queries. A team of experts within the American Association of Pharmaceutical Scientists' Therapeutic Product Immunogenicity Community across industry and the Food and Drug Administration addressed challenges unique to cell-based and non-cell-based neutralizing antibody assays. Harmonization of validation expectations and data reporting will facilitate filings to health authorities and are described in this manuscript. This team provides validation testing and reporting strategies and tools for the following assessments: (1) format selection; (2) cut point; (3) assay acceptance criteria; (4) control precision; (5) sensitivity including positive control selection and performance tracking; (6) negative control selection; (7) selectivity/specificity including matrix interference, hemolysis, lipemia, bilirubin, concomitant medications, and structurally similar analytes; (8) drug tolerance; (9) target tolerance; (10) sample stability; and (11) assay robustness.

Anti-drug Antibody Sample Testing and Reporting Harmonization.

A clear scientific and operational need exists for harmonized bioanalytical immunogenicity study reporting to facilitate communication of immunogenicity findings and expedient review by industry and health authorities. To address these key bioanalytical reporting gaps and provide a report structure for documenting immunogenicity results, this cross-industry group was formed to establish harmonized recommendations and a develop a submission template to facilitate agency filings. Provided here are recommendations for reporting clinical anti-drug antibody (ADA) assay results using ligand-binding assay technologies. This publication describes the essential bioanalytical report (BAR) elements such as the method, critical reagents and equipment, study samples, results, and data analysis, and provides a template for a suggested structure for the ADA BAR. This publication focuses on the content and presentation of the bioanalytical ADA sample analysis report. The interpretation of immunogenicity data, including the evaluation of the impact of ADA on safety, exposure, and efficacy, is out of scope of this publication.

Morphine sulfate concomitantly decreases neuronal differentiation and opioid receptor expression in mouse embryonic stem cells.

Opioids have been shown to affect prenatal and postnatal neural development in mammals. The present study investigates the impact of morphine sulfate (MS) treatment on neuronal differentiation as well as µ-opioid receptor (MOR) expression in mouse embryonic stem (mES) cells. Stem cells were manipulated in culture to differentiate in 3 sequential stages: Stage 1, cell transformation to embryoid bodies (EB); Stage 2, EB cell differentiation to neural progenitor (NP) cells; and, Stage 3, NP cell differentiation to neurons/astrocytes co-cultured cells. Using RT-PCR and flow cytometry analyses, cell types were confirmed by monitoring expression of Oct4, nestin, microtubule-associated protein 2 (mtap-2), and glial fibrillary acidic protein (GFAP) as cell-specific markers for stem cells, NP cells, neurons, and astrocytes, respectively. Similarly, gene expression for MOR, κ-opioid receptor (KOR), and δ-opioid receptor (DOR) was confirmed in each cell type. In order to investigate the effects of MS on differentiation, cells were treated with MS (1, 10, 100 µM) at either early (Stage 1) or late (Stage 3) stage of cellular differentiation. At Stage 1 exposure, MOR gene expression and neuroectoderm specific marker expression of nestin were down-regulated in both EB and NP cells. In addition, the opioid down-regulated GFAP in differentiated neurons/astrocytes co-cultured cells. Late stage treatment with MS resulted in a down-regulation of mtap-2 and GFAP in differentiated neurons/astrocytes co-cultured cells. Moreover, late stage treatment with MS and naltrexone inhibited the effect of MS on neuronal differentiation, suggesting that MS treatment interferes with differentiation via MOR activation. Together, the results show that MS exposure at early and late stage of cellular differentiation significantly decreases genotype and phenotype in differentiated neuronal cells. The results of this study have implications regarding the potential effect of opiates on fetal brain development.

Assessment of phagocytic activity of cultured macrophages using fluorescence microscopy and flow cytometry.

Phagocytosis is the process by which phagocytes, including macrophages, neutrophils and monocytes, engulf and kill invading pathogens, remove foreign particles, and clear cell debris. Phagocytes and their ability to phagocytose are an important part of the innate immune system and are critical for homeostasis of the host. Impairment in phagocytosis has been associated with numerous diseases and disorders. Different cytokines have been shown to affect the phagocytic process. Cytokines including TNFα, IL-1ß, GM-CSF, and TGF-ß1 were found to promote phagocytosis, whereas high mobility group box-1 (HMGB1) inhibited the phagocytic function of macrophages. Here, we describe two commonly used methods to assess the phagocytic function of cultured macrophages, which can easily be applied to other phagocytes. Each method is based on the extent of engulfment of FITC-labeled latex minibeads by macrophages under different conditions. Phagocytic activity can be assessed either by counting individual cells using a fluorescence microscope or measuring fluorescence intensity using a flow cytometer.

Alternative methods for ocular toxicology testing: validation, applications and troubleshooting.

INTRODUCTION: Humanitarian concern, scientific progress and legislative action have lead to the development, validation and regulatory acceptance of alternative in vitro ocular models. However, to date not a single in vitro alternative ocular toxicity test has been validated as a full replacement for the in vivo Draize rabbit eye test for all classes of chemicals across whole irritancy ranges. Since the 1990s, ocular alternative methods have been validated but few have been accepted for regulatory purposes. These assays include: organotypic models, such as the bovine corneal opacity and permeability (BCOP) assay, the isolated chicken eye (ICE) test method and cell function-based in vitro assays, such as the cytosensor microphysiometer (CM) and the fluorescein leakage (FL) test methods. Some refinements to in vivo testing methods have been accepted by regulatory agencies, including humane endpoints to avoid or minimize pain and distress. AREAS COVERED: The authors provide a review of the background, protocol overview, applications and their validation status of the tier-testing approach. Furthermore, the authors provide expert analysis and provide their perspective on this approach and potential future developments. EXPERT OPINION: In the search for a battery of methods that replaces the in vivo Draize test, it is necessary to prioritize techniques, define related mechanisms and justify statistical approaches. Overall, only when the reliability and relevance of a method is unequivocally supported will any technique be ready for regulatory acceptance.

Protective effect of diosmin on LPS-induced apoptosis in PC12 cells and inhibition of TNF-α expression.

Several studies have demonstrated a link between increased pro-inflammatory mediators and apoptosis in neurodegenerative diseases. It has been reported that lipopolysaccharide (LPS) induces apoptosis mostly through the production of TNF-α. In this study, we investigated the possible protective and anti-inflammatory mechanisms of diosmin, a natural flavone glycoside, on LPS-induced PC12 cells death through inhibition of TNF-α production. PC12 Cells were pretreated with diosmin for 2h prior to LPS treatment for 48 h to assess PC12 cells viability, TNF-α expression, and cell death mechanisms. Diosmin significantly increased cells survival and suppressed LPS-induced TNF-α in a concentration-dependent manner. Diosmin also significantly reduced the DNA fragmentation of LPS-induced cells, and its anti-apoptotic effect was confirmed by the decrease in the expression of pro-apoptotic protein Bad and the increase in the expression of anti-apoptotic protein Bcl-2 on Western blot analysis. Furthermore, diosmin inhibited LPS-induced caspase-3 activation further confirming its anti-apoptotic effects. This is the first study to report the anti-inflammatory and anti-apoptotic effects of diosmin via inhibition of TNF-α and a caspase-dependent pathway in neuronal PC12 cells. These results support the potential for diosmin to be investigated as a potential agent for the treatment of neurodegenerative diseases.